

# Ãna C Mc Menamin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5454681/publications.pdf>

Version: 2024-02-01

40  
papers

1,058  
citations

394286

19  
h-index

434063

31  
g-index

40  
all docs

40  
docs citations

40  
times ranked

1970  
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-pharmacological interventions for cognitive impairment due to systemic cancer treatment. The Cochrane Library, 2022, 2022, CD011325.	1.5	49
2	The impact of the COVID-19 pandemic on endometrial cancer and endometrial hyperplasia diagnoses: a population-based study. American Journal of Obstetrics and Gynecology, 2022, 226, 737-739.e2.	0.7	5
3	Survival outcomes in endometrial cancer patients according to diabetes: a systematic review and meta-analysis. BMC Cancer, 2022, 22, 427.	1.1	8
4	Hormone therapy use and the risk of acute kidney injury in patients with prostate cancer: a population-based cohort study. Prostate Cancer and Prostatic Diseases, 2021, 24, 1055-1062.	2.0	4
5	Circulating Sex Hormones Are Associated With Gastric and Colorectal Cancers but Not Esophageal Adenocarcinoma in the UK Biobank. American Journal of Gastroenterology, 2021, 116, 522-529.	0.2	18
6	Statin use and risk of liver cancer: Evidence from two population-based studies. International Journal of Cancer, 2020, 146, 1250-1260.	2.3	48
7	The Risk of Cardiovascular Disease in Prostate Cancer Patients Receiving Androgen Deprivation Therapies. Epidemiology, 2020, 31, 432-440.	1.2	22
8	Exogenous hormone use, reproductive factors and risk of intrahepatic cholangiocarcinoma among women: results from cohort studies in the Liver Cancer Pooling Project and the UK Biobank. British Journal of Cancer, 2020, 123, 316-324.	2.9	20
9	Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0232231.	1.1	73
10	Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies. British Journal of Cancer, 2020, 123, 307-315.	2.9	21
11	Title is missing!. , 2020, 15, e0232231.		0
12	Title is missing!. , 2020, 15, e0232231.		0
13	Title is missing!. , 2020, 15, e0232231.		0
14	Title is missing!. , 2020, 15, e0232231.		0
15	Furosemide use and survival in patients with esophageal or gastric cancer: a population-based cohort study. BMC Cancer, 2019, 19, 1017.	1.1	6
16	The association between self-reported poor oral health and gastrointestinal cancer risk in the UK Biobank: A large prospective cohort study. United European Gastroenterology Journal, 2019, 7, 1241-1249.	1.6	23
17	Coffee consumption by type and risk of digestive cancer: a large prospective cohort study. British Journal of Cancer, 2019, 120, 1059-1066.	2.9	27
18	Information on Genetic Variants Does Not Increase Identification of Individuals at Risk of Esophageal Adenocarcinoma Compared to Clinical Risk Factors. Gastroenterology, 2019, 156, 43-45.	0.6	15

#	ARTICLE	IF	CITATIONS
19	Hormonal and reproductive factors and risk of upper gastrointestinal cancers in men: A prospective cohort study within the UK Biobank. <i>International Journal of Cancer</i> , 2018, 143, 831-841.	2.3	8
20	Medications that relax the lower oesophageal sphincter and risk of oesophageal cancer: An analysis of two independent population-based databases. <i>International Journal of Cancer</i> , 2018, 143, 22-31.	2.3	10
21	Model for Identifying Individuals at Risk for Esophageal Adenocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1229-1236.e4.	2.4	41
22	Blood biomarkers for early diagnosis of oesophageal cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 263-273.	0.8	14
23	Physical activity, sedentary behaviour and risk of oesophago-gastric cancer: A prospective cohort study within UK Biobank. <i>United European Gastroenterology Journal</i> , 2018, 6, 1144-1154.	1.6	20
24	Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 55-64.	1.9	36
25	Vitamin D receptor as a marker of prognosis in oesophageal adenocarcinoma: a prospective cohort study. <i>Oncotarget</i> , 2018, 9, 34347-34356.	0.8	7
26	Sex hormone receptor expression and survival in esophageal adenocarcinoma: a prospective cohort study. <i>Oncotarget</i> , 2018, 9, 35300-35312.	0.8	6
27	Low-dose aspirin use and survival in breast cancer patients: A nationwide cohort study. <i>Cancer Epidemiology</i> , 2017, 47, 20-27.	0.8	20
28	Low-dose aspirin use and survival in breast cancer patients: A nationwide cohort study. <i>Cancer Epidemiology</i> , 2017, 48, 158.	0.8	2
29	Do smoking and alcohol behaviours influence GI cancer survival?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 569-577.	1.0	16
30	Commonly used medications and endometrial cancer survival: a population-based cohort study. <i>British Journal of Cancer</i> , 2017, 117, 432-438.	2.9	25
31	Adenocarcinoma risk in gastric atrophy and intestinal metaplasia: a systematic review. <i>BMC Gastroenterology</i> , 2017, 17, 157.	0.8	66
32	Metformin use and survival after colorectal cancer: A population-based cohort study. <i>International Journal of Cancer</i> , 2016, 138, 369-379.	2.3	47
33	Statin use and breast cancer survival: a nationwide cohort study in Scotland. <i>BMC Cancer</i> , 2016, 16, 600.	1.1	46
34	Metformin use and survival from lung cancer: A population-based cohort study. <i>Lung Cancer</i> , 2016, 94, 35-39.	0.9	35
35	Low-dose aspirin and survival from lung cancer: a population-based cohort study. <i>BMC Cancer</i> , 2015, 15, 911.	1.1	21
36	Digoxin use after diagnosis of breast cancer and survival: a population-based cohort study. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 661-669.	1.1	7

#	ARTICLE	IF	CITATIONS
37	Statin Use and Survival from Lung Cancer: A Population-Based Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 833-841.	1.1	106
38	Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts. <i>BMC Medicine</i> , 2014, 12, 28.	2.3	49
39	PTGS2 (Cyclooxygenase-2) Expression and Survival among Colorectal Cancer Patients: A Systematic Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1490-1497.	1.1	62
40	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. <i>Cancer Causes and Control</i> , 2012, 23, 221-230.	0.8	75